Περίληψη:
BackgroundAfter the first investigational study on the use of
extracorporeal photopheresis for the treatment of cutaneous T-cell
lymphoma was published in 1983 with its subsequent recognition by the
FDA for its refractory forms, the technology has shown significant
promise in the treatment of other severe and refractory conditions in a
multi-disciplinary setting. Among the major studied conditions are graft
versus host disease after allogeneic bone marrow transplantation,
systemic sclerosis, solid organ transplant rejection and inflammatory
bowel disease.
Materials and methodsIn order to provide recognized expert practical
guidelines for the use of this technology for all indications the
European Dermatology Forum (EDF) proceeded to address these questions in
the hands of the recognized experts within and outside the field of
dermatology. This was done using the recognized and approved guidelines
of EDF for this task.
Results and conclusionThese guidelines provide at present the most
comprehensive available expert recommendations for the use of
extracorporeal photopheresis based on the available published literature
and expert consensus opinion.
Συγγραφείς:
Knobler, R.
Berlin, G.
Calzavara-Pinton, P.
Greinix, H. and
Jaksch, P.
Laroche, L.
Ludvigsson, J.
Quaglino, P. and
Reinisch, W.
Scarisbrick, J.
Schwarz, T.
Wolf, P. and
Arenberger, P.
Assaf, C.
Bagot, M.
Barr, M.
Bohbot, A.
and Bruckner-Tuderman, L.
Dreno, B.
Enk, A.
French, L. and
Gniadecki, R.
Gollnick, H.
Hertl, M.
Jantschitsch, C. and
Jung, A.
Just, U.
Klemke, C. -D.
Lippert, U.
Luger, T.
and Papadavid, E.
Pehamberger, H.
Ranki, A.
Stadler, R. and
Sterry, W.
Wolf, I. H.
Worm, M.
Zic, J.
Zouboulis, C. C.
and Hillen, U.
